Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers

Executive Summary

While risks clearly outweigh benefits for niacin as an add-on therapy in the more than 25,000-patient HPS2-THRIVE study, investigators argue that the door is still open for other HDL-raising drugs. One panelist at the ACC meeting where results were presented calls for smaller, more targeted trials in the future.

Advertisement

Related Content

DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck's REVEAL Genetic Analysis
Merck Calls It Quits On Anacetrapib
Merck Calls It Quits On Anacetrapib
Who Suffers From Lilly's Evacetrapib Failure?
CETP Inhibitors Back In The Fold: Amgen Dives In With Dezima Buy
After Statins, Rise Of The Subgroups? IMPROVE-IT Suggests Population Choice Key
Tredaptive Safety Hazards Cast Shadow Over AbbVie’s Niaspan
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel